Meropenem Versus Piperacillin-Tazobactam for Definitive Treatment of Bloodstream Infections Caused by AmpC β-Lactamase-Producing Enterobacter spp, Citrobacter freundii , Morganella morganii , Providencia spp, or Serratia marcescens : A Pilot Multicenter Randomized Controlled Trial (MERINO-2).

MLA

Stewart, Adam G., et al. “Meropenem Versus Piperacillin-Tazobactam for Definitive Treatment of Bloodstream Infections Caused by AmpC β-Lactamase-Producing Enterobacter Spp, Citrobacter Freundii , Morganella Morganii , Providencia Spp, or Serratia Marcescens : A Pilot Multicenter Randomized Controlled Trial (MERINO-2).” Open Forum Infectious Diseases, vol. 8, no. 8, Aug. 2021, p. ofab387. EBSCOhost, https://doi.org/10.1093/ofid/ofab387.

APA

Stewart, A. G., Paterson, D. L., Young, B., Lye, D. C., Davis, J. S., Schneider, K., Yilmaz, M., Dinleyici, R., Runnegar, N., Henderson, A., Archuleta, S., Kalimuddin, S., Forde, B. M., Chatfield, M. D., Bauer, M. J., Lipman, J., Harris-Brown, T., & Harris, P. N. A. (2021). Meropenem Versus Piperacillin-Tazobactam for Definitive Treatment of Bloodstream Infections Caused by AmpC β-Lactamase-Producing Enterobacter spp, Citrobacter freundii , Morganella morganii , Providencia spp, or Serratia marcescens : A Pilot Multicenter Randomized Controlled Trial (MERINO-2). Open Forum Infectious Diseases, 8(8), ofab387. https://doi.org/10.1093/ofid/ofab387

Chicago

Stewart, Adam G, David L Paterson, Barnaby Young, David C Lye, Joshua S Davis, Kellie Schneider, Mesut Yilmaz, et al. 2021. “Meropenem Versus Piperacillin-Tazobactam for Definitive Treatment of Bloodstream Infections Caused by AmpC β-Lactamase-Producing Enterobacter Spp, Citrobacter Freundii , Morganella Morganii , Providencia Spp, or Serratia Marcescens : A Pilot Multicenter Randomized Controlled Trial (MERINO-2).” Open Forum Infectious Diseases 8 (8): ofab387. doi:10.1093/ofid/ofab387.